Medifast is undergoing a critical strategic pivot from a traditional direct-selling meal-replacement model to a medically integrated metabolic health platform. The rapid rise of GLP-1 weight-loss medications has severely disrupted its core business, leading to a 44.9% year-over-year decline in active earning coaches to 14,000 in Q1 2026. However, early signs of stabilization are emerging, highlighted by a 19.2% year-over-year increase in coach productivity (revenue per active earning coach of $5,432) and the company's first sequential revenue growth in three years. Backed by a debt-free balance sheet with $168.9 million in cash and investments, and guided by newly appointed CEO Nicholas Johnson, Medifast has the financial runway to execute its transformation. Activist involvement from Steamboat Capital Partners further ensures disciplined capital allocation. While the long-term potential of its 'Metabolic Synchronization' science and LifeMD telehealth partnership is promising, near-term profitability remains under pressure, making a Hold recommendation appropriate until sustainable top-line growth is re-established.